Neuropacs is a Gainesville-based neurological technology company building automated MRI processing and machine-learning software to assist in diagnosing Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Its platform uses a single, non-invasive diffusion MRI scan on standard 3-Tesla equipment and applies a free-water imaging model coupled with a rigorously validated algorithm to detect neurodegeneration. Clinicians receive a clear output indicating the probable disorder, aiming to improve diagnostic accuracy and speed. With the newly secured capital, Neuropacs plans to accelerate core technology development, hire key talent, and forge strategic partnerships ahead of broader clinical commercialization. Management positions the product as radiotracer-free and clinically practical, targeting widespread adoption in neurology practices. The company’s early investors view the technology as transformative for neurological care, underscoring market confidence. To date Neuropacs has raised just over $1 million in seed funding; no additional operating metrics were disclosed.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026